中国临床药理学杂志2024,Vol.40Issue(22) :3328-3332.DOI:10.13699/j.cnki.1001-6821.2024.22.022

生脉散治疗慢性心力衰竭的临床应用现状

Current status of clinical application of Shengmaisan in the treatment of chronic heart failure

耿新冉 杨硕
中国临床药理学杂志2024,Vol.40Issue(22) :3328-3332.DOI:10.13699/j.cnki.1001-6821.2024.22.022

生脉散治疗慢性心力衰竭的临床应用现状

Current status of clinical application of Shengmaisan in the treatment of chronic heart failure

耿新冉 1杨硕2
扫码查看

作者信息

  • 1. 辽宁中医药大学第四临床学院,辽宁沈阳 110847
  • 2. 辽宁中医药大学附属第四医院心血管内科,辽宁沈阳 110847
  • 折叠

摘要

慢性心力衰竭(CHF)有较高的发病率和死亡率,中医运用生脉散在治疗CHF方面具有独特的优势.生脉散可以改善心力衰竭患者的临床症状,提高生活质量,其主要通过抑制神经内分泌系统、抑制免疫炎症反应、抑制心肌纤维化、抑制心肌细胞凋亡、抗氧化应激反应、降低Ca2+泄露增加心肌收缩力等多种途径来发挥作用.本文对近年来生脉散治疗CHF进行论述,以期能更好地应用于临床.

Abstract

Chronic heart failure(CHF)has high morbidity and mortality.The application of Shengmaisan in traditional Chinese medical science has unique advantage in the treatment of chronic heart failure.Shengmaisan can improve the clinical symptoms and quality of life of patients with heart failure.It mainly plays its role through inhibition of neuroendocrine system,inhibition of immune inflammation response,inhibition of myocardial fibrosis,inhibition of cardiomyocyte apoptosis,anti-oxidative stress response,reduced Ca2+leakage and increase myocardial contractility.This article discusses the treatment of chronic heart failure with Shengmaisan in recent years,in order to better clinical application.

关键词

生脉散/慢性心力衰竭/临床应用/作用机制

Key words

Shengmaisan/chronic heart failure/clinical application/mechanism of action

引用本文复制引用

出版年

2024
中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCDCSCD北大核心
影响因子:1.91
ISSN:1001-6821
段落导航相关论文